改善黑色素瘤高危人群皮肤自查及其他自我管理依从性的策略:随机临床试验的范围综述
本范围综述检索4个数据库至2022年7月,纳入18项随机临床试验,评估改善黑色素瘤高危人群自我监测依从性的策略及其测量与报告方式。依从性策略分为试验设计、社会与经济支持、干预设计、干预与条件支持及参与者支持五类,但对策略有效性的证据稀疏,且未报告针对弱势群体的策略。依从性数据报告有限,不足半数报告在讨论中提及依从性。
要点
- 共纳入18项随机临床试验,样本量40至724人,策略分类包括试验设计、社会与经济支持、干预设计、干预与条件支持及参与者支持。
- 无策略报告支持弱势群体(如社会经济弱势、健康素养低、非英语使用者或老年人)坚持自我监测实践,仅5项试验针对提供者依从性。
- 依从性测量通常基于参与者报告的皮肤自查实践,部分数字干预试验通过网站或应用程序分析数据直接测量依从性;依从性数据报告有限,不足半数报告在讨论中提及依从性。
核心结论
- 本范围综述采用世界卫生组织临床依从性框架的改编版,识别了黑色素瘤高危人群皮肤自查及其他自我管理试验在依从性方法、实施和报告方面的关键概念与差距,这些发现可能有助于指导未来试验和临床实践,依从性策略的评估或可在宿主试验内通过试验内研究(SWAT)框架进行。
研究设计与样本
- 检索MEDLINE、Embase、CENTRAL和CINAHL四个数据库,从建库至2022年7月,纳入因个人史(如黑色素瘤、移植、发育不良痣综合征)、家族史或风险评价工具/临床判断确定为高危人群的自我监测干预随机临床试验。
主要发现
- 从939条筛选记录中纳入18项符合条件的随机临床试验,样本量40至724人,使用多种依从性策略但策略有效性证据稀疏。
- 策略分类为试验设计(n=15)、社会与经济支持(n=5)、干预设计(n=18)、干预与条件支持(n=10)和参与者支持(n=18)。
- 无策略报告支持弱势群体(如社会经济弱势、健康素养低、非英语使用者或老年人)坚持自我监测实践,仅5项试验针对提供者(临床医生和研究者)依从性。
- 行为支持工具包括提醒(n=8)、优先级设定指导(n=5)和临床医生反馈(n=5)。
- 依从性测量通常基于参与者报告的皮肤自查实践,部分近期数字干预试验还通过网站或应用程序分析数据直接测量依从性;依从性数据报告有限,不足半数报告在讨论中提及依从性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Adherence, both in research trials and in clinical practice, is crucial to the success of interventions. There is limited guidance on strategies to increase adherence and the measurement and reporting of adherence in trials of melanoma self-management practices. OBJECTIVE: This scoping review aimed to describe (1) strategies to improve adherence to self-management practices in randomized clinical trials of people at high risk of melanoma and (2) measurement and reporting of adherence data in these trials. EVIDENCE REVIEW: Four databases, including MEDLINE, Embase, CENTRAL, and CINAHL, were searched from inception to July 2022. Eligible studies were randomized clinical trials of self-monitoring interventions for early detection of melanoma in people at increased risk due to personal history (eg, melanoma, transplant, dysplastic naevus syndrome), family history of melanoma, or as determined by a risk assessment tool or clinical judgment. FINDINGS: From 939 records screened, 18 eligible randomized clinical trials were identified, ranging in size from 40 to 724 participants, using a range of adherence strategies but with sparse evidence on effectiveness of the strategies. Strategies were classified as trial design (n = 15); social and economic support (n = 5); intervention design (n = 18); intervention and condition support (n = 10); and participant support (n = 18). No strategies were reported for supporting underserved groups (eg, people who are socioeconomically disadvantaged, have low health literacy, non-English speakers, or older adults) to adhere to self-monitoring practices, and few trials targeted provider (referring to both clinicians and researchers) adherence (n = 5). Behavioral support tools included reminders (n = 8), priority-setting guidance (n = 5), and clinician feedback (n = 5). Measurement of adherence was usually by participant report of skin self-examination practice with some recent trials of digital interventions also directly measuring adherence to the intervention through website or application analytic data. Reporting of adherence data was limited, and fewer than half of all reports mentioned adherence in their discussion. CONCLUSIONS AND RELEVANCE: Using an adaptation of the World Health Organization framework for clinical adherence, this scoping review of randomized clinical trials identified key concepts as well as gaps in the way adherence is approached in design, conduct, and reporting of trials for skin self-examination and other self-management practices in people at high risk of melanoma. These findings may usefully guide future trials and clinical practice; evaluation of adherence strategies may be possible using a Study Within A Trial (SWAT) framework within host trials.
引用
- Ackermann DM, Bracken K, Janda M, et al. Strategies to Improve Adherence to Skin Self-examination and Other Self-management Practices in People at High Risk of Melanoma: A Scoping Review of Randomized Clinical Trials. JAMA Dermatol. 2023. PMID: 36857048. doi:10.1001/jamadermatol.2022.6478
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。